IA-WORKIVA
20.10.2021 14:02:05 CEST | Business Wire | Press release
Workiva Inc. (NYSE:WK), the company that simplifies complex work, announced the winners of the 2021 Workiva Partner of the Year Awards. The awards recognize partners that have leveraged their significant industry and solution-specific experience to help customers expand their use of the Workiva platform to drive transparency in reporting and compliance. Award recipients were recognized during the Company’s virtual Global Partner Summit , held October 18 & 19.
“Our partners are instrumental in deploying the Workiva platform as a critical component in digital transformations across global enterprises,” said Corey Wells, vice president of partnerships and alliances at Workiva. “It’s an honor to recognize this year’s winners for helping drive the innovation and collaboration that has made a lasting impact on our customers' business.”
2021 Partner of the Year Award Winners
- Global Partner of the Year - Deloitte
- Global Technology Partner of the Year - FloQast
- North American Advisory Partner of the Year - PwC US
- North American Mid-Market Advisory Partner of the Year - Clearview Group
- North American Emerging Partner of the Year - DHG
- EMEA Partner of the Year - PwC Germany
- EMEA Emerging Partner of the Year - Advance Tax Compliance
- APAC Partner of the Year - PwC Hong Kong , PwC Japan , and PwC Taiwan
- Partner Innovation Award Winner - F.H. Black
More about the 2021 Partner of the Year Award Winners
Advance Tax Compliance (ATC) delivers high-quality implementations and supports the Workiva sales team with new clients. ATC is also an active contributor to Workiva marketing events, client demos and the Workiva Marketplace.
Clearview Group * has been named the North American Mid-Market Advisory Partner of the Year two years in a row. Clearview Group has a masterful understanding of Workiva solutions and delivers a compelling value story. Clearview Group has grown with Workiva, from supporting integrated risk management to developing a comprehensive service line, delivering advisory and transformation services powered by collaboration across management reporting, and financial reporting as well.
Deloitte * has been named global partner of the year two years in a row. Deloitte collaborates globally with Workiva, introducing the company to new customers, identifying new use cases and supporting sales teams. Deloitte has been instrumental in communicating the value of the Workiva platform and helping global customers use innovative technology to help address complex business problems.
DHG , a top 20 public accounting, tax, and advisory firm, helped bring Workiva’s Global Statutory Reporting (GSR) and Environmental, Social, and Governance (ESG) offerings to market. DHG’s global teams work across EMEA and North America with Workiva to help joint customers, which include some of the largest companies in the world, navigate the complexities of GSR and ESG reporting.
F.H. Black * is a groundbreaking services partner that has elevated and extended the most technically advanced aspects of the Workiva platform. F.H. Black's innovative methodology and investment into collaborating with the Workiva product teams have helped tailor Workiva’s solutions for the public sector, specifically the development of Government Finance Officers Association (GFOA) compliant financial reports, budget books, Governmental Accounting Standards Board (GASB) 87 solutions and State-mandated solutions.
FloQast * has won the Global Technology Partner of the Year award two years in a row. FloQast continues to bring extreme value to Workiva and their joint customers with their accounting workflow automation solution. FloQast also invested in developing a direct API into the Workiva platform to provide joint customers increased visibility of the Close to Report process that spans the Finance, Accounting and Reporting teams.
PwC* has a dedicated alliance team with a depth of experience that helps strengthen Workiva's global position as a strategic platform for businesses. PwC collaborates with Workiva globally across all use cases and seeks opportunities to embed Workiva into PwC tech-enabled offerings. PwC continually invests and grows their Workiva-focused resources and is dedicated to accelerating the success of Workiva and their shared, global customers. PwC was recognized for three regional awards: North American Partner of the Year (PwC US), EMEA Partner of the Year (PwC Germany), and APAC Partner of the Year (PwC Hong Kong, PwC Japan, and PwC Taiwan).
*Denotes Workiva Marketplace Innovator. Marketplace Innovators played a crucial role in the launch of the Workiva Marketplace by contributing meaningful templates, services and content that were readily available for customers to add to their workspaces and use upon the launch of the marketplace in August, 2021.
About Workiva
Workiva Inc. (NYSE: WK) simplifies complex work for thousands of organizations worldwide. Customers trust Workiva’s open, intelligent and intuitive platform to connect data, documents and teams. The results: improved efficiency, greater transparency and less risk. Learn more at workiva.com .
Read the Workiva blog: www.workiva.com/blog
Follow Workiva on LinkedIn: www.linkedin.com/company/workiva
Like Workiva on Facebook: www.facebook.com/workiva/
Follow Workiva on Twitter: www.twitter.com/Workiva
Follow Workiva on Instagram: www.instagram.com/workivalife
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005117/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom